Quick Search 
Drugs of the Future
Register or sign in

Volume 47, Issue 9, September 2022, Pages 635-710
Fixed-dose combination, Cephalosporin β-lactam antibiotic/β-lactamase inhibitor, Treatment of complicated urinary tract infection.
Santani, B.G., LeBlanc, B.W., Thakare, R.P.
Drugs Fut 2022, 47(9): 635
Summary | Full Text: PDF 
Microtubule destabilizer (tubulin polymerization inhibitor), Tumor checkpoint controller, Treatment of advanced glioblastoma multiforme.
Tiu, C., Lopez, J.
Drugs Fut 2022, 47(9): 651
Summary | Full Text: PDF 
ALK/ROS1/TRK inhibitor, Treatment of solid tumors.
Li, Z., Bo, L., Talukder, S., Ping, F-F., Chen, Z.-S.
Drugs Fut 2022, 47(9): 661
Summary | Full Text: PDF 
 Therapeutic targets for dermatomyositis.
Sorbera, L.A., Dulsat, C., Graul, A.I.
Drugs Fut 2022, 47(9): 675
Summary | Full Text: PDF 
 Pipeline on the Move.
Betolin, L.F.
Drugs Fut 2022, 47(9): 681
Full Text: PDF 
 Experimental and in silico approaches to target selection and tractability for drug discovery. Highlights from the Society for Medicines Research Conference. London – March 21, 2022.
Hann, M.M., Peace, S., Skerratt, S., Hirst, D., Butterworth, S.
Drugs Fut 2022, 47(9): 693
Summary | Full Text: PDF 
 American Society for Microbiology (ASM) Microbe – 2022 Annual Meeting. Washington, D.C. – June 9-13, 2022.
Nguyen, J.
Drugs Fut 2022, 47(9): 701
Summary | Full Text: PDF 
 European Association for Cancer Research (EACR) – 28th Annual Meeting. Seville – June 20-23, 2022.
Dulsat, C.
Drugs Fut 2022, 47(9): 707
Summary | Full Text: PDF 

© 2022 Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences